二十二烷酸甘油单酯 | 30233-64-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 二十二烷酸甘油单酯
• 中文别名: 二十二酸-1,2,3-丙三醇单酯；甘油山嵛酸酯
• 英文名称: glycerol behenate
• 英文别名: glyceryl monobehenate；docosanoic acid 2',3'-dihydroxypropyl ester；docosanoic acid monoglyceride；2,3-dihydroxypropylbehenate；glyceryl 1-monobehenate；1-O-docosanoylglycerol；Glyceryl behenate；2,3-dihydroxypropyl docosanoate
• CAS: 30233-64-8
• 化学式: C₂₅H₅₀O₄
• 分子量: 414.67
• InChiKey: OKMWKBLSFKFYGZ-UHFFFAOYSA-N

物化性质

• 密度：
  0.93[at 20℃]
• 溶解度：
  Soluble, when heated, in chloroform and dichloromethane and in many organic solvents; slightly soluble in hot ethanol (96%); practically insoluble in cold ethanol (95%), hexane, mineral oil, and water.
• LogP：
  8.58 at 25℃

计算性质

• 辛醇/水分配系数(LogP)：
  9.6
• 重原子数：
  29
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性方面，Monobehenin 是一种高效的细菌生物膜抑制剂，能够显著抑制宋氏链球菌（S. mutans）、水稻链球菌（X. oryzae）和肠炎耶尔森菌（Y. enterocolitica）的生物膜形成。

反应信息

• 作为反应物：
  描述：

  二十二烷酸甘油单酯 、 O²,O³-diacetyl-tartaric acid anhydride 生成
  参考文献：
  名称：

  Study of the Effect of DATEM. 1. Influence of Fatty Acid Chain Length on Rheology and Baking

  摘要：

  To answer the question of which fatty acid residue is the most effective, diacetyltartaric esters of monoglycerides (DATEMs) with fatty acids of chain lengths 6:0-20:0 were synthesized. The activity of synthesized DATEMs and commercial DATEM products was studied by means of rheological methods and a microscale baking test with 10 g of flour. Variation of the acyl residue from 6:0 to 22:0 showed that stearic acid (18:0) had the best effect on the baking activity of DATEM (loaf volume increased by 62%). DATEMs containing unsaturated fatty acids (18:1, 18:2) or DATEMs produced from diacylglycerols instead of monoacylglycerols showed a slight increase of the loaf volumes. A slight effect of DATEM on the rheology of dough was observed. However, much greater was the effect on the gluten isolated from doughs prepared with DATEM. The resistance of gluten to extension was increased after the addition of increasing amounts of DATEM (0.1-0.5%). Within the series of DATEMs derived from the homologous series of monoacylglycerols the product based on glycerol monostearate (18:0) showed a maximum increase of the gluten resistance.

  DOI：

  10.1021/jf980891i
• 作为产物：
  描述：

  二十二酰氯 在 吡啶 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 二十二烷酸甘油单酯
  参考文献：
  名称：

  Synthesis of glycerolipids containing simple linear acyl chains or aromatic rings and evaluation of their Mincle signaling activity

  摘要：

  合成的甘油酯衍生物具有简单的烷基链，可刺激与先天性免疫系统相关的 Mincle 介导的信号检测。

  DOI：

  10.1039/c8cc07322h

文献信息

• PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY
  申请人：Rewcastle Gordon William

  公开号：US20110009405A1

  公开（公告）日：2011-01-13

  Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

  本文提供了式I的嘧啶基和1,3,5-三嗪基苯并咪唑化合物，以及它们的药物组合物、制备方法，以及作为抗癌治疗药物或药剂的用途，可以单独使用，也可以与放疗和/或其他抗癌药物联合使用。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'ATHÉROTROMBOSE
  申请人：KANDULA MAHESH

  公开号：WO2013024376A1

  公开（公告）日：2013-02-21

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.

  本公开提供公式I的化合物或其药用可接受的盐，以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以用于口服、经皮、经粘膜、糖浆、局部、延长释放、持续释放或注射的给药。这种组合物可用于治疗血管疾病或病况，如血栓性脑血管或心血管疾病或其相关并发症。
• [EN] COMPOSITIONS AND METHODS FOR TREATING ATHEROTHROMBOSIS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA THROMBOSE ATHÉROSCLÉREUSE
  申请人：KANDULA MAHESH

  公开号：WO2013168022A1

  公开（公告）日：2013-11-14

  Provided are compounds of formula (I), pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injection, and may be used for the treatment or management of ischemia, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.

  提供的是式(I)的化合物，药用可接受的盐，多型体，溶剂合物，对映体，立体异构体及其水合物。包含这些化合物的药物组合物可用于口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂的配制，并可用于治疗或管理缺血、脑血栓形成、动脉血栓形成、血栓性脑血管疾病、心血管疾病和血栓。
• [EN] CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS<br/>[FR] MACROLIDES A LIAISON CARBAMATE UTILISES DANS LE TRAITEMENT DES INFECTIONS MICROBIENNES
  申请人：PLIVA ISTRAZIVACKI INST D O O

  公开号：WO2005108413A1

  公开（公告）日：2005-11-17

  The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

  本发明涉及在式(I)的4'位置被取代的14-或15-元大环内酯及其药学上可接受的衍生物，以及它们的制备过程和在人体或动物体内治疗或预防全身或局部微生物感染中的用途。
• Novel Compounds
  申请人：Chhipa Laxmikant

  公开号：US20100168110A1

  公开（公告）日：2010-07-01

  The present invention discloses a novel thyroid like compounds of formula (I), wherein R 1 R 2 , R 3 , R 4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

  本发明公开了一种新型的甲状腺类似化合物，其化学式为（I），其中R1、R2、R3、R4和Z如规范中所定义，以及其制备方法、含有这种化合物的组合物和这种化合物及组合物作为药物的用途。此外，化合物的化学式（I）具有与甲状腺受体显著低的结合亲和力，因此在很大程度上缺乏甲状腺毒性作用。该发明还涉及将化学式（I）的化合物用于制备用于治疗肥胖、血脂异常、代谢综合征以及与代谢综合征相关的合并症等各种疾病状况的药物。